DePuy Synthes reports Australian Joint Registry data confirm positive early results with Attune Knee System
Click Here to Manage Email Alerts
Implant survivorship data from the 2016 Australian Orthopaedic Association National Joint Replacement Registry confirm positive early results for the DePuy Synthes Attune Knee System, DePuy Synthes, part of the Johnson & Johnson Family of Companies, recently announced in a press release.
The 2016 Australian Orthopaedic Association National Joint Replacement Registry, in which 4,831 Attune knee prostheses were tracked, estimated a cumulative percent revision of 0.5% for the cruciate-retaining design and 0.4% for the posterior-stabilized design of the Attune knee at 1 year, according to the release. It was noted in the release that these 1-year data compare favorably to the 1% estimated cumulative percent revision for the overall class of cemented total knee arthroplasty (TKA).
“There is a steady cadence of evidence for the Attune knee that suggests improved outcomes and functional performance” Paul Voorhorst, vice president of Clinical Research for DePuy Synthes Joint Reconstruction, said in the release. “We are committed to ongoing monitoring of both the outcomes and economic benefits of this new technology.”
This news follows an announcement late in 2016 in which evidence from the National Joint Registry for England, Wales, Northern Ireland and the Isle of Man showed survivorship of the Attune Knee compared favorably to other cemented TKA systems in its class.
“These promising early results are encouraging for patients, health care providers and payers, and underline the importance of our robust evidence generation program for the Attune knee,” Christina Farup, vice president of Health Economics and Market Access, Johnson & Johnson Medical Devices. “We designed the Attune Knee System with both patients and providers in mind to help health care systems increase patient satisfaction, improve clinical outcomes and reduce overall health care costs.”
Reference: